Business
Appointment of Shore Capital as Joint Broker
Appointment of Shore Capital as Joint Broker.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 5818F Oxford BioDynamics PLC 19 May 2017 \n\n19 May 2017\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\")\n \nAppointment of Shore Capital as Joint Broker\n \nOxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce the appointment of Shore Capital Stockbrokers Limited (\"Shore Capital\") as joint broker to the Company, with immediate effect.\n \nFor further details contact:\n \n\n\n\n\nOxford BioDynamics Plc\n\n\n \n\n\n+44 (0)1865 518910\n\n\n\n\nChristian Hoyer Millar, CEO\n\n\n \n\n\n \n\n\n\n\nKatie Long, CFO\n\n\n \n\n\n \n\n\n\n\n \n\n\n \n\n\n \n\n\n\n\nStifel Nicolaus Europe Limited\n\n\n \n\n\n+44 (0)20 7710 7600\n\n\n\n\nNominated Advisor and Broker\n\n\n \n\n\n \n\n\n\n\nDavid Arch\n\n\n \n\n\n \n\n\n\n\nJonathan Senior\n\n\n \n\n\n \n\n\n\n\nPeter Lees\n\n\n \n\n\n \n\n\n\n\nBen Maddison\n\n\n \n\n\n \n\n\n\n\n \n\n\n \n\n\n \n\n\n\n\nShore Capital\n\n\n \n\n\n+44 (0)20 7408 4090\n\n\n\n\nJoint Broker \n\n\n \n\n\n \n\n\n\n\nBidhi Bhoma\n\n\n \n\n\n \n\n\n\n\nEdward Mansfield\n\n\n \n\n\n \n\n\n\n\n \n\n\n \n\n\n \n\n\n\n\nFTI Consulting \n\n\n \n\n\n+44 (0)20 3727 1000\n\n\n\n\nFinancial Public Relations Advisor\n\n\n \n\n\n \n\n\n\n\nJulia Phillips\n\n\n \n\n\n \n\n\n\n\nBrett Pollard\n\n\n \n\n\n \n\n\n\n\nNatalie Garland-Collins\n\n\n \n\n\n \n\n\n\n\n \n \nNotes for Editors\n \nAbout Oxford BioDynamics Plc\n \nOxford BioDynamics Plc (AIM: OBD) (\"Oxford BioDynamics\") is a revenue‐generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. \n \nThe Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of person...